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Abstract Catching primal functional changes in early, ‘very far from disease onset’ (VFDO)
stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO
stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo
two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex
- one of the first regions affected in premanifest Huntington’s disease - characterized by an
increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are
accompanied by aberrations in animal behavior. We furthermore show that the antidiabetic drug
metformin diminishes aberrant Huntingtin protein load and fully restores both early network
activity patterns and behavioral aberrations. This network-centered approach reveals a critical
window of vulnerability far before clinical manifestation and establishes metformin as a promising
candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis
long before the onset of clinical symptoms.
DOI: https://doi.org/10.7554/eLife.38744.001
Introduction
Huntington’s disease is caused by the expansion of a CAG repeat in the open-reading frame of the
huntingtin gene (HTT), which translates into an expanded glutamine stretch in the aberrant, mutant
protein (mHTT). Huntington’s disease has primarily been described as a late-onset neurodegenera-
tive disease. However, it is preceded in its premanifest period by a prolonged
presymptomatic phase followed by a prodromal phase with hardly detectable and unspecific symp-
toms occurring far before classical Huntington’s disease becomes apparent (Ross et al., 2014).
These symptoms include reduced impulse control, social disengagement, low conversational partici-
pation, reduction of the concentration span and decline of clearly defined cognitive domains
(Stout et al., 2011; Predict-HD Investigators of the Huntington Study Group et al., 2007;
Ross et al., 2014; Labuschagne et al., 2016) and are accompanied by slight changes of cortical
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network topology and functional connectivity in resting state fMRI measures (PREDICT-
HD investigators of the Huntington Study Group et al., 2015; Wolf et al., 2012). Importantly,
such subtle network dysregulations may occur even earlier than the described prodromal symptoms
in a very far from disease onset (VFDO) premanifest stage (Figure 1a). This stage reaches back more
than 15–20 years before motor symptoms become visible in patients and far before protein aggre-
gates and neurodegeneration are observed.
In Huntington’s disease occurrence of such very early changes is supported by the observation of
early deficits in premanifest Huntington’s disease mutation carriers, such as loss of phosphodiester-
ase 10A in the occipital lobe up to 47 years prior to disease onset (summarized in Wilson et al.,
2017). Also, the ability to perform complex visuospatial orientation, such as visual search, seems to
be altered even in pre-manifest stages far from clinical diagnosis (Labuschagne et al., 2016). We
hypothesize that primal functional changes in the VFDO stage of premanifest Huntington’s disease
open up very early vulnerable windows for disease development and preventive therapy prior to
neuronal loss and may also provide promising early biomarkers for therapy development
(Mehler and Gokhan, 2000; Kerschbamer and Biagioli, 2015; Humbert, 2010; Cepeda et al.,
2003).
It seems that the visual cortex is one of the first regions that are functionally affected during dis-
ease development in Huntington’s disease (Labuschagne et al., 2016; Dogan et al., 2013). In order
to identify primal network changes, we have here established a network-centered approach and
focused on microcircuit function in layer 2/3 of the visual cortex at an early premanifest stage in a
mouse model of Huntington’s disease corresponding to the VFDO stage in premanifest Huntington’s
disease. We have used two-photon imaging using fluorescent indicators of intracellular Ca2+ in order
to resolve the functional architecture of intact cortical microcircuits in vivo with single neuron resolu-
tion (Grienberger and Konnerth, 2012). We show that even at the early age of 10 – 15 weeks
(young adults compared to humans), the entire cortical microcircuit shifts towards a more excitable
eLife digest Huntington’s disease is a devastating brain disorder that causes severe mood
disorders, problems with moving, and dementia. Most people develop the condition between their
thirties and fifties, and die a decade or two after the symptoms first appear.
The disease emerges because of a mutation in the gene for the Huntingtin protein, which leads
to neurons slowly dying in the brain. While genetic testing can reveal who carries the faulty gene, no
treatment addresses the root of the disorder or prevents it from appearing. Instead, most therapies
for Huntington’s disease aim to reduce brain damage once the telltale symptoms are already
present. However, the disease-causing protein is expressed early during the life of a patient, which
could give it time to damage the brain long before neurons die and the disorder reveals itself.
Treatments that start after the first signs of the disease may be too late to reverse the damage.
Detecting and preventing early brain changes in people that carry the mutation may thus help to
stop the disease from progressing.
Here, Arnoux, Willam, Griesche et al. set out to detect the minute changes that the faulty
Huntingtin protein may cause in the brain network of young mice with the mutation. State-of-the-art
imaging tools helped to examine individual neurons in the brain area that processes visual
information. These experiments revealed that a group of brain cells had become hyperactive; once
this change had occurred, the mutant animals were less anxious than is typical for mice.
Metformin is a drug used to treat diabetes, but it also interferes with a structure that is required
to produce the disease-causing Huntingtin protein. Arnoux et al. therefore explored whether the
compound could rescue the early brain alterations observed in mutant mice. Adding metformin in
the water of the animals for three weeks halted the production of the mutant protein, reversed the
brain changes and stopped the abnormal behavior.
Further work is now required in humans to confirm that Huntington’s disease starts with a change
in the activity of networks in the brain, and to verify that metformin can stop the disorder in its track.
DOI: https://doi.org/10.7554/eLife.38744.002
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Figure 1. In vivo two-photon Ca2+ imaging in layer 2/3 of visual cortex reveals a hyperactive neuronal activity pattern prior to disease onset. (a,b) Top
right, Illustrations indicating the visual cortex (blue area) in human (a) and mouse (b) brains. The brains are not drawn to scale. Bottom, timeline of
Huntington’s disease progression in human and Hdh150 mouse model of Huntington’s disease. The Huntington’s disease onset was age 30–50 years in
humans and ~70 weeks in Hdh150 mice. We conducted our experiments during a very early pre-symptomatic phase, far prior to mHtt aggregates and
Figure 1 continued on next page
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state characterized by a complex change in neuronal activity pattern and hyperactive neurons. These
findings are accompanied by changes in animal behavior, including a decrease in anxiety.
No effective and curative treatment has been developed for Huntington’s disease so far
(Frank, 2014). A chronic drug therapy that commences early on in VFDO stages in premanifest Hun-
tington’s disease and ameliorates early dysregulations as the potential origin of pathogenic pro-
cesses and disease spreading is therefore a promising and necessary strategy. In Huntington’s
disease animal models, even short-term reduction of protein load through RNA interference and
antisense strategies has beneficial effects on disease phenotypes and progression lasting several
months after intervention (Stanek et al., 2014; DiFiglia et al., 2007; Keiser et al., 2016). We have
recently shown that mRNAs carrying CAG repeats bind to a protein complex containing the ubiqui-
tin ligase midline 1 (MID1) in a repeat size-dependent manner. Through ubiquitination MID1 regu-
lates PP2A (protein phosphatase 2A) and mTOR (mechanistic target of rapamycin) activities and the
translation of associated mRNAs (Krauss et al., 2013; Griesche et al., 2016). Disruption of the
MID1/PP2A/mTOR protein complex leads to an increase of PP2A activity, a decrease of mTOR activ-
ity and a reduction of translation rates of mRNAs with expanded CAG repeats (Krauss et al., 2013).
We show here that the type II diabetes drug metformin interferes with the MID1/PP2A/mTOR
protein complex and significantly reduces the translation rate of Htt mRNA, resulting in a reduction
of aberrant Htt protein production in vitro and in vivo in the Hdh150 mouse model. Notably, in
Hdh150 mice in vivo metformin, when given early in the VFDO stage, and chronically in the drinking
water, fully reverses both early neuronal network dysregulations and behavioral aberrations.
Figure 1 continued
motor symptoms. VFDO: very far from disease onset. (c) Representative two-photon images of OGB-1 AM staining in layer 2/3 of the visual cortex of
WT and Hdh150 mice. Scale bar: 70 mm. (d) Color-coded maps of silent (black) and spontaneously active (orange) neurons in WT (left) and Hdh150
(right) mice. Dashed lines represent the boundaries of blood vessels (original images in Figure 1c). Scale bar: 100 mm. (e) Density of stained cells in
layer 2/3 of the visual cortex in WT and Hdh150 mice. Unpaired t-test, p=0.71. (f) Increased proportion of spontaneously active neurons in Hdh150 mice.
Unpaired t-test, p<0.05. (g) Representative traces of spontaneous Ca2+ transients (red) of 10 neurons recorded in vivo in WT and Hdh150 mice. Vertical
scale bars: 40% dF/F. (h) Increased frequency of Ca2+ transients in spontaneously active neurons of Hdh150 mice. Silent neurons were excluded, as in
subsequent panels. Mann-Whitney test, p<0.01 (i) Quantification of area under the curve (AUC) of Ca2+ transients. Unpaired t-test, p=0.98 (j) Cumulative
frequency distribution of Ca2+ transients in WT (dark grey) and Hdh150 (red) mice. Top, colored categorization of neurons according to their Ca2+
transient frequencies. Two-way ANOVA, group: p<0.0001, time: p<0.0001, Interaction: p<0.0001. (k) Color-coded categorization of neurons according
to their Ca2+ transient frequency: ‘low’ (<0.3 trans/min, blue; silent neurons excluded), ‘medium’ (0.3–3 trans/min, orange) and ‘hyper’ (>3 trans/min,
red). Each peak is marked by an asterisk. (l) Relative proportion of low, medium and hyperactive neurons in layer 2/3 of the visual cortex in WT (left) and
Hdh150 (right) mice. Chi-square test, p<0.01.
DOI: https://doi.org/10.7554/eLife.38744.003
The following video, source data, and figure supplements are available for figure 1:
Source data 1. Numerical values of Figure 1 and associated supplement figures.
DOI: https://doi.org/10.7554/eLife.38744.007
Source data 2. Code used for the analysis of calcium imaging.
DOI: https://doi.org/10.7554/eLife.38744.008
Figure supplement 1. Ca2+ events from astrocytes and neurons show clearly distinct kinetics.
DOI: https://doi.org/10.7554/eLife.38744.004
Figure supplement 2. Cortical hyperactivity is independent of mHtt aggregation, astrogliosis or apoptotic cell death in presymptomatic VFDO Hdh150
mice.
DOI: https://doi.org/10.7554/eLife.38744.005
Figure supplement 3. Randomization of experimental data to assess specific spatial clustering.
DOI: https://doi.org/10.7554/eLife.38744.006
Figure 1—video 1. In vivo two-photon images of mouse visual cortex performed at different depths (indicated in the upper left corner) after multi-bolus
loading with OGB-1 AM.
DOI: https://doi.org/10.7554/eLife.38744.009
Figure 1—video 2. Representative time-lapse of in vivo two-photon Ca2+ imaging acquired in layer 2/3 of mouse visual cortex showing single-cell Ca2+
transients.
DOI: https://doi.org/10.7554/eLife.38744.010
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Results
Increase in cortical neuronal network activity in presymptomatic
Huntington’s disease mice
Since the visual cortex is one of the first regions affected by the disease (Dogan et al., 2013;
Labuschagne et al., 2016), we focused on layer 2/3 of the visual cortex of ~12 weeks old, heterozy-
gous knock-in mice expressing expanded Htt with 150 glutamine repeats (Hdh150), in the lightly
anesthetized mouse. This time corresponds to the VFDO in presymptomatic Huntington’s disease
(Figure 1a,b). We focused our analysis on male mice, thereby minimizing the influence of hormonal
fluctuations on network activity. This approach is in line with a recent study in the field of Alzheimer’s
disease (Iaccarino et al., 2016), using males only. We employed two-photon Ca2+ imaging in vivo
using the synthetic Ca2+ indicator Oregon-Green BAPTA1 (OGB-1) AM to monitor the suprathres-
hold activity of a neuronal microcircuit with cellular resolution, typically comprising around 200 neu-
rons (Kerr et al., 2005) (Figure 1c, Figure 1—figure supplement 1a,b). Events from astrocytes,
which are also stained by OGB-1, were excluded from this neuronal network based on their temporal
dynamics (Figure 1—figure supplement 1c–f, Figure 1—source data 1).
By imaging at different depths, we found a similar spatial extent of OGB-1 staining in the visual
cortex of Hdh150 and control wild-type (WT) mice (Figure 1—figure supplement 1b). Figure 1—
video 1 shows two-photon images acquired from the pial surface illustrating a homogenous OGB-1
staining in layers 1, 2 and 3 of mouse visual cortex. We observed no difference in the density of
stained cells (Figure 1c and e, Figure 1—source data 1, WT: 1413 ± 74 cells/mm2 (n = 11 mice),
Hdh150 1456 ± 90 cells/mm2 (n = 10 mice), Mann-Whitney test p=0.8).
To identify changes in microcircuit activity, we assessed spontaneous activity in vivo in the cortical
microcircuit of WT and Hdh150 mice, which reliably reflects the functional microarchitecture of sen-
sory cortical areas (Miller et al., 2014). Figure 1—video 2 shows an example of in vivo two-photon
Ca2+ imaging exhibiting ongoing spontaneous activity in layer 2/3 of mouse visual cortex with sin-
gle-cell resolution. Both WT and Hdh150 mice exhibited silent and active cells (Figure 1d), but a sig-
nificantly higher proportion of active neurons was detected in Hdh150 mice, indicating a more active
network (Figure 1f, Figure 1—source data 1, WT: 65.1 ± 3.5% (n = 8 mice), Hdh150: 77.1 ± 3.5%
(n = 6 mice), unpaired t-test p<0.05). No spatial clustering of silent or active cells could be observed
in either group (Figure 1d).
Next, we analyzed the frequency of Ca2+ transients and activity patterns in the population of
active neurons (Figure 1—source data 2). Notably, the frequency of Ca2+ transients was significantly
higher in Hdh150 compared to WT mice (Figure 1g–h, Figure 1—source data 1, WT: 0.74 ± 0.06
trans/min (n = 8 mice), Hdh150: 1.2 ± 0.14 trans/min (n = 6 mice), Mann-Whitney test, p<0.01). No
difference was found in the mean area under the curve (AUC) of Ca2+ transients between WT and
Hdh150 mice (Figure 1i, Figure 1—source data 1, WT: 39.8 ± 3.9 (dF/f)*s, Hdh150: 39.9 ± 3.6 (dF/f)
*s, unpaired t-test, p=0.98) indicating that on average, the mean number of underlying action poten-
tials for each individual calcium transient was not different in Hdh150 mice.
We furthermore analyzed the distribution of neurons according to their Ca2+ transient frequency.
The cumulative probability distribution of the activity of individual neurons in Huntington’s disease
mice was shifted toward higher frequencies indicating that the overall neuronal activity transitioned
toward a more excitable network (Figure 1j, Figure 1—source data 1, two-way ANOVA p<0.0001).
We sub-classified the active neurons into three functional subgroups according to their transient fre-
quency: low, medium and hyperactive (Figure 1k, Figure 1—source data 1). Notably, we identified
a unique subgroup in VFDO Hdh150 mice: hyperactive neurons (Figure 1l, Figure 1—source data
1, Chi-square test p<0.01). This subgroup was accompanied by a reduction in the number of neu-
rons with low activity, which corroborates the shift of the microcircuit activity.
In later stages of Alzheimer’s disease, hyperactive cells were shown to cluster near amyloid pla-
ques (Busche et al., 2008). A similar scenario might occur in Huntington’s disease. To clarify whether
the cortex of VFDO Hdh150 mice is affected by mHtt aggregates - a later stage Huntington’s dis-
ease hallmark - we performed immunohistochemistry in Hdh150 and WT animals. We observed only
diffuse and non-aggregated Htt immunoreactivity in the cytoplasm of neurons in cortical areas of
both WT and Hdh150 mice (Figure 1—figure supplement 2a) in accordance with previous studies
(Lin et al., 2001). In addition, no reactive astrocytes were observed (Figure 1—figure supplement
2b) and only few cells that were stained for activated caspase-3, an apoptotic marker, in cortical
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areas of WT and Hdh150 mice (Figure 1—figure supplement 2c) as previously observed (Yu et al.,
2003). In order to test whether hyperactive cells cluster in the Hdh150 mouse model, spatial dis-
tance between every pair of neurons was quantified (Figure 1—figure supplement 3c,d, Figure 1—
source data 1). We observed no significant differences between the permutations of functional sub-
groups in premanifest Hdh150 and control mice, reflecting a rather homogenous distribution of all
functional subgroups (Figure 1—figure supplement 3c,d, Figure 1—source data 1, Mann-Whitney,
not significant, see Table 1 for p-values). This finding was confirmed in randomized data in which
cell location was kept but functional identity was randomly permutated (Figure 1—figure supple-
ment 3a,b and d, Figure 1—source data 1). Taken together, clustering of hyperactive cells could
not be observed in VFDO Hdh150 animals and cortical hyperactivity is independent of mHtt aggre-
gation, apoptotic cell death or astrogliosis at this presymptomatic VFDO stage.
Increased synchronicity and cortical dysfunction in premanifest VFDO
Huntington’s disease mice
An important aspect of neuronal information processing is the optimization of encoding strategies.
In the visual cortex, encoding of information is characterized by sparse and precisely timed neuronal
activity. Cortical activity is defined by transiently co-active ensembles of neurons acting as a func-
tional unit (Miller et al., 2014). To capture these spatiotemporal dynamics in the microcircuit, we
analyzed synchronicity of the transients between all pairs of neurons (Figure 2a) by calculating Pear-
son’s correlation coefficient (Pearson’s r) for every pair. First, we confirmed that the level of synchro-
nicity within a healthy cortical microcircuit is drastically higher than the random synchronicity in
shuffled data (Figure 2b, Figure 2—source data 1, WT: 0.024 ± 0.005, WT rand:  0.0003 ± 0.0003,
Mann-Whitney test p<0.0001). Notably, the synchronicity was even higher in Hdh150 mice compared
to healthy controls (Figure 2b, Figure 2—source data 1, WT: 0.02 ± 0.005, Hdh150: 0.04 ± 0.006,
Mann-Whitney test p<0.05).
Next, we compared the synchronicity level in all functional subgroups (Figure 2c, Figure 2—
source data 1). The pairs involving the low activity subgroups (LL and LM) showed no differences in
WT and Hdh150 mice (Mann-Whitney test, in LL p=0.5 and in LM p=0.7). However, Pearson’s r
increased significantly for the medium-to-medium (MM) pairs in Hdh150. Pearson’s r was even higher
for medium-hyperactive (MH) and hyperactive-hyperactive (HH) compared to low-low (LL) pairs
(Mann-Whitney test compared to LL in Hdh150 mice: in MM p<0.05, in MH and HH p<0.01).
To assess whether the increased synchronicity in the VFDO Hdh150 mice occurred merely due to
the higher number of transients, we used randomized data with unchanged frequency but tempo-
rally shuffled transients (Figure 1—figure supplement 3a and b). Pearson’s r in the randomized
data was nearly zero for all, including the high frequency subgroups in WT and Hdh150 mice (Fig-
ure 2—figure supplement 1a and b, Figure 2—source data 1). This finding argued against the pos-
sibility that the increased Pearson’s r in the experimental data occurred by chance.
We next asked whether functional ensembles with a high level of synchronicity are located in spa-
tial vicinity to each other, by testing whether Pearson’s r changed with physical distance between
the pairs of neurons (Figure 2d). An inverse linear relationship was observed between Pearson’s r
and the pairwise distance in both the WT and Hdh150 mice (Figure 2d, Figure 2—source data 1,
two-way ANOVA p<0.0001, WT vs Hdh150) suggesting that two closely located neurons have a
higher probability to fire together. This is consistent with similar findings in the forelimb motor cor-
tex of head-restrained mice (Dombeck et al., 2009). Randomization of the data abolished the
inverse relationship between Pearson’s r and distance (Figure 2e, Figure 2—source data 1, two-
way ANOVA p=0.3, WT rand vs Hdh150 rand).
Since many studies, especially in premanifest mutation carriers, have linked Huntington’s disease
pathology to changes in metabolism (Damiano et al., 2010; Duan et al., 2014; Jin and Johnson,
2010; Labbadia and Morimoto, 2013; Mochel and Haller, 2011), hyperactivity might mirror meta-
bolic dysregulation in subgroups of cortical cells. We used mitochondrial respiration as a marker of
metabolic functionality and quantified mitochondrial respiration using high-resolution respirometry
of cortical tissues. Mitochondrial respiration was unchanged in cortical tissue of Hdh150 mice sug-
gesting that the observed neuronal hyperactivity occurs prior to metabolic changes (Figure 2—fig-
ure supplement 2a–c, Figure 2—source data 1, Mann-Whitney test, not significant, see Table 1 for
p-values).
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Table 1. Statistics
Figure Test Values N
Figure 1e Unpaired t
test, two-
tailed
NS, p=0.71 WT n = 11 mice; Hdh150
n = 10 mice
Figure 1f Unpaired t
test, two-
tailed
p=0.023 WT n = 1204 cells in eight
mice;
Hdh150 n = 933 cells in six
mice
Figure 1h Mann-Whitney
test
p=0.006 WT n = 765 cells in eight
mice;
Hdh150 n = 695 cells in six
mice
Figure 1i Unpaired t
test, two-
tailed
NS, p=0.98 WT n = 765 cells in eight
mice;
Hdh150 n = 695 cells in six
mice
Figure 1j Two-way
ANOVA test
Group: p<0.0001, Df = 1, F = 85.96, time: p<0.0001, Df = 16, F = 147, Interaction:
p<0.0001, F = 4.9, Df = 16
WT n = 765 cells in eight
mice;
Hdh150 n = 695 cells in six
mice
Figure 1l Chi-square
test
p=0.002, df = 1, Chi-square = 9.127 WT n = 765 cells in eight
mice;
Hdh150 n = 695 cells in six
mice
Figure 2b Mann-Whitney
test
WT vs Hdh150 p=0.03; WT vs WT rand p<0.0001; Hdh150 vs Hdh150 rand p<0.0001 WT n = 26126 Pearson’s r in
eight
mice; Hdh150 n = 58050
Pearson’s
r in six mice
Figure 2c Mann-Whitney
test
WT vs Hdh150 mice: MM p=0.041 in Hdh150 mice; compared to LL: MM p=0.0496,
MH p=0.005, HH p=0.009
WT n = 26126 Pearson’s r in
eight
mice; Hdh150 n = 58050
Pearson’s r in six mice
Figure 2d Two-way
ANOVA test
Group: p<0.0001, Df = 1, F = 58.20
Distance: p=0.97, Df = 15, F = 0.44
Interaction: p=0.33, df = 15, F = 1.13
WT n = 26126 distances in
eight mice; Hdh150
n = 58050 distances in six
mice
Figure 2e Two-way
ANOVA test
p=0.35, Df = 1, F = 0.86 WT rand n = 26126 distances
in eight mice; Hdh150 rand
n = 58050 distances in six
mice
Figure 3b Mann-Whitney
test
p=0.031119 WT n = 10 mice; Hdh150
n = 13 mice
Figure 4a Mann-Whitney
test
control vs 1 mM metformin p=0.084521, control vs 2.5 mM metformin p=0.023231 Control n = 10, 1 mM
metformin
n = 11, 2.5 mM metformin
n = 10.
Figure 4b Mann-Whitney
test
control siRNA vs MID1 siRNA p=0.008, control siRNA vs MID1 siRNA + metformin
p=0.015
Control siRNA n = 6, MID1
siRNA
n = 6, MID1
siRNA + metformin n=6.
Figure 4c RM two-way
ANOVA
Treatment: p=0.0082, Df = 2, F = 5
Time: p<0.0001, Df = 47, F = 27.5
Interaction: p<0.0001, Df = 94, F = 5.9
ncontrol = 47, nmetformin
1mM = 44,
nmetformin 2.5mM = 35
Figure 4d RM two-way
ANOVA
Treatment: p=0.0021, Df = 3, F = 5.1
Time: p<0.0001, Df = 47, F = 64.1
Interaction: p<0.0001, Df = 141, F = 6.1 p<0.0001
ncontrol = 46, nmetformin = 49,
nmetformin+OA = 51, nOA = 43
Figure 4f Unpaired
t-test
p=0.0473 Hdh150 n = 6; Hdh150
metformin n = 6
Figure 4h Unpaired
t-test
p=0.0467 Hdh150 n = 3; Hdh150
metformin n = 3
Table 1 continued on next page
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Table 1 continued
Figure Test Values N
Figure 4i Unpaired
t-test
p=0.0062 Hdh150 n = 3; Hdh150
metformin n = 3
Figure 4j Unpaired
t-test
p=0.8766 Hdh150 n = 3; Hdh150
metformin n = 3
Figure 5b Mann-Whitney
test
WT vs Hdh150 p=0.023, Hdh150 vs Hdh150 met p=0.03, Hdh150 vs WT met p=0.012 WT n = 1204 cells in eight
mice;
Hdh150 n = 933 cells in six
mice;
WT met n = 1915 cells in nine
mice;
Hdh150 met n = 1585 cells in
six mice
Figure 5c Mann-Whitney
test
WT vs Hdh150 p=0.006; Hdh150 vs Hdh150 met p=0.007; Hdh150 vs WT met p=0.008 WT n = 765 cells in eight
mice;
Hdh150 n = 695 cells in six
mice;
WT met n = 1199 in nine
mice;
Hdh150 met n = 1014 cells in
six mice
Figure 5d Two-way
ANOVA test
Group: p<0.0001, Df = 3, F = 61.80
Time: p<0.0001, Df = 16, F = 345.9
Interaction: p<0.0001, Df = 48, F = 3.64
WT n = 765 cells eight mice;
Hdh150 n = 695 cells six
mice;
WT met n = 1199 cells nine
mice;
Hdh150 met n = 1012 cells
six
mice
Figure 5e Chi-square
test
p=0.62, df = 1; Chi-square = 0.24 WT n = 765 cells eight mice;
Hdh150 n = 695 cells six
mice;
WT met n = 1199 cells nine
mice;
Hdh150 met n = 1012 cells
six mice
Figure 5f Mann-Whitney
test
WT vs Hdh150 p=0.03; Hdh150 vs Hdh150 met p=0.002; Hdh150 vs WT met p=0.003 WT n = 765 cells eight mice;
Hdh150 n = 695 cells six
mice;
WT met n = 1199 cells nine
mice;
Hdh150 met n = 1012 cells
six mice
Figure 5g Two-way
ANOVA test
Group: p<0.0001, Df = 3, F = 85.96
Distance: p=0.99, Df = 45, F = 0.58
Interaction: p=0.0007, Df = 15, F = 2.63
WT n = 765 cells eight mice;
Hdh150 n = 695 cells six
mice;
WT met n = 1199 cells nine
mice;
Hdh150 met n = 1012 cells
six mice
Figure 5i Mann-Whitney
test
WT vs Hdh150 p=0.002, Hdh150 vs Hdh150 Met p=0.002, Hdh150 vs. WT met p=0.02,
WT vs Hdh150 Met p=0.82
WT n = 10; Hdh150 n = 13;
WT
met n = 6; Hdh150 met n = 8
mice
Figures
supplements
Test values n
Figure 1—figure
supplement 1e
Mann-Whitney
test
p=0.002 n = 6 neurons, n = 6
astrocytes
Figure 1—figure
supplement 1f
Mann-Whitney
test
p=0.002 n = 6 neurons, n = 6
astrocytes
Table 1 continued on next page
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Table 1 continued
Figure Test Values N
Figure 1—figure
supplement 3d
Mann-Whitney
test
In WT mice: SS vs SL p=0.5, SS vs SM p=0.9, SS vs LL p=0.1, SS vs LM p=0.2, SS vs MM
p=0.1, SL vs SM p=0.4, SM vs LL p=0.1, SM vs MM p=0.1, LL vs MM p=0.9, LM vs MM
p=0.4, LM vs SM, p=0.2.
In Hdh150 mice: SS vs SL p=0.8, SS vs SM p=0.5, SS vs SH p=0.9, SS vs SH p=0.9, SS
vs LL p=0.9, SS vs LM p=0.9, SS vs LH p=1, SS vs MM p=0.1, SS vs MH p=0.1, SS vs HH
p=0.4, SL vs SM p=0.8, SL vs SH p=0.9, SL vs LL p=0.9, SL vs LM p=0.9, SL vs LH
p=0.8, SL vs MM p=0.5, SL vs MH p=0.6, SL vs HH p=0.7, SN vs SH p=0.6, SM vs LL
p=0.7, SM vs LM p=0.6, SN vs LH p=0.4, SM vs MM p=0.3, SN vs MH p=0.4, SN vs HH
p 0 0.6, SH vs LL p=0.7, SH vs LM p=1, SH vs LH p=1, SH vs MM p=0.4, SH vs MH
p=0.3, SH vs HH p=0.6, LL vs LM p=0.9, LL vs LH p=1, LL vs MM p=0.5, LL vs MH
p=0.7, LL vs HH p=0.8, LM vs LH p=0.6, LM vs MM p=0.3, LM vs MH p=0.3, LM vs HH
p=0.5, LH vs MM p=0.3, LH vs MH p=0.3, LH vs HH p=0.5, MM vs MH p=0.7, NN vs
HH p=0.8, MH vs HH p=0.9
In WT vs WT rand: WT mice: SS p=0.5, SL p=0.7, SM p=0.3, LL p=0.3, LM p=0.8, MM
p=0.1.
In Hdh150 vs Hdh150 rand: SS p=0.6, SL p=1, SM p=1, SH p=0.6, LL p=0.7, LM p=0.6,
LH p=0.2, MM p=0.6, MH p=0.8, HH p=0.7 NS
WT n = 72595 distances
eight
mice; Hdh150 n = 132009
distances six mice
Figure 2—figure
supplement 1a
Mann-Whitney
test
LL p=0.005; LM p<0.0001; MM p<0.0001 WT n = 26126 Pearson’s
r in eight mice
Figure 2—figure
supplement 1b
Mann-Whitney
test
LL p=0.004; LM p=0.0006; LH p=0.041; MM p<0.0001; MH p=0.0002; HH p=0.01. In
Hdh150 mice, compared to LL: MM p=0.049; MH p=0.005; HH p=0.009
Hdh150 n = 58050 Pearson’s
r in six mice
Figure 2—figure
supplement 2c
Mann-Whitney
test
routine p=0.4, leak p=0.5, CI p=0.6, CI + CII p=0.5, ETS p=0.2 WT n = 6 mice; Hdh150
n = 6 mice
Figure 3—figure
supplement 1b
RM two-way
ANOVA
Genotype: p=0.6, Df = 1, F = 0.3
Time: p<0.0001, Df = 6, F = 86.1
Interaction: p=0.6, Df = 6, F = 0.7
WT n = 16 mice; Hdh150
n = 13 mice
Figure 3—figure
supplement 1c
RM two-way
ANOVA
Genotype: p=0.5, Df = 1, F = 0.5
Time: p<0.0001, Df = 9, F = 35.4
Interaction: p=0.03, Df = 9, F = 2.2
WT n = 16 mice; Hdh150
n = 13 mice
Figure 3—figure
supplement 1d
RM two-way
ANOVA
Genotype: p=0.8, Df = 1, F = 3.4
Time: p<0.01, Df = 6, F = 3.4
Interaction: p=0.97, Df = 6, F = 0.2
WT n = 16 mice; Hdh150
n = 13 mice
Figure 3—figure
supplement 1e
Mann-Whitney
test
p=0.3 WT n = 10; Hdh150 n = 13;
WT
met n = 6; Hdh150 met n = 8
mice
Figure 4—figure
supplement 1a
RM two-way
ANOVA
Treatment p=0.0342, Df = 2, F = 3.5;
Time p<0.0001, Df = 47, F = 45.3; Interaction p<0.0001, Df = 94, F = 3.5
ncontrol = 36, nmetformin
1mM = 42,
nmetformin 2.5mM = 44
Figure 4—figure
supplement 1b
RM two-way
ANOVA
Treatment p=0.2986, Df = 1, F = 1.9;
Time p=0.0654, Df = 20, F = 1.8;
Interaction p=0.9988, Df = 20, F = 0.3.
control n = 7, metformin
n = 8
Figure 4—figure
supplement 1dc
Unpaired
t-test
p=0,1826 Hdh150 n = 4; Hdh150
metformin
n = 4
Figure 4—figure
supplement 2a
Mann-Whitney
test
p<0.0001 control n = 65, metformin
n = 65
Figure 4—figure
supplement 2b
Mann-Whitney
test
Q40 vs. Q40 Met p<0.0001 Q40n = 43, Q40 Met n = 43
Figure 4—figure
supplement 2c
Mann-Whitney
test
Ctrl vs. 5 mM p=0.0078, Ctrl vs. 10 mM p<0.0001 n = 45
Figure 4—figure
supplement 2d
Mann-Whitney
test
p<0.0001 Control n = 72, arc-1 RNAi
n = 74
Figure 4—figure
supplement 2e
Mann-Whitney
test
p<0.0001 Control n = 60, arc-1 RNAi
n = 62
Figure 5—figure
supplement 1b
Unpaired t
test, two-
tailed
WT met vs. Hdh150 met p=0.39, WT vs. WT met p=0.7, Hdh150 vs. Hdh150 met p=0.9 WT n = 11; Hdh150 n = 10;
WT met
n = 9; Hdh150 met n = 6
mice
Table 1 continued on next page
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Behavior changes in premanifest VFDO Huntington’s disease mice
Next, we asked whether hyperactivity and increased synchronicity of cortical networks are associated
with behavioral changes in the VFDO animals. A visual discrimination task did not show any aberra-
tions in the Hdh150 animals (Figure 3—figure supplement 1a–d; Figure 3—video 1, Figure 3—
source data 1, two-way ANOVA, not significant, see Table 1 for p-values). In contrast, in an open-
field test premanifest VDFO Hdh150 animals moved significantly more to the center than WT litter-
mates suggesting anxiolytic effects of the VFDO changes (Figure 3a,b, Figure 3—source data 1,
Mann-Whitney test, p=0.03). Distance travelled (as a measure of motility) did not differ between
groups (Figure 3—figure supplement 1e, Figure 3—source data 1, Mann-Whitney test, not signifi-
cant, see Table 1 for p-values).
Taken together, we have found network hyperactivity in the cortex of VFDO Hdh150 mice com-
bined with anxiolytic behavior.
Metformin reduces mutant Htt protein load
Based on our previous observations that the MID1/PP2A/mTOR protein complex regulates the trans-
lation of mHtt protein (Krauss et al., 2013) and that treatment with metformin interferes with the
MID1 complex (Kickstein et al., 2010), we hypothesized that metformin inhibits the MID1/PP2A/
mTOR-mediated protein synthesis of mutant mHtt and is therefore a promising candidate molecule
to reduce mHtt load and reverse symptoms associated with Huntington’s disease.
In order to test for an effect of metformin on mHtt protein load and aggregation, HEKT cells sta-
bly expressing FLAG-tagged exon 1 of human mHTT carrying 83 CAG repeats were treated with 1
mM or 2.5 mM metformin, or with vehicle for 48 hr. Aggregation was quantified in a filter retarda-
tion assay. Metformin reduced the amount of aggregated FLAG-HTT in a concentration-dependent
manner (Figure 4a, Figure 4—source data 1, Mann-Whitney test, control vs 2.5 mM metformin
p=0.02).
To test whether the metformin effect on human exon 1 mHTT aggregates is mediated by a block-
ade of the MID1 protein complex, we depleted MID1 by siRNA-mediated knockdown in the cell line
expressing FLAG-HTT exon 1 with 83 CAG repeats, in presence or absence of metformin. While
depletion of MID1 reduced mHTT aggregation, no additive effect of metformin treatment on mHTT
Table 1 continued
Figure Test Values N
Figure 5—figure
supplement 1c
Unpaired t
test, two-
tailed
WT vs WT met p=0.024 WT n = 765 cells eight mice;
Hdh150 n = 695 cells six
mice;
WT met n = 1199 cells nine
mice; Hdh150
met n = 1012 cells six mice
Figure 5—figure
supplement 1d
Unpaired t
test, two-
tailed
WT met: LL vs LM p=0.04 and LL vs MM p<0.0001; Hdh150 met: LL vs LM p=0.4, LL vs
MM p=0.004
WT met n = 57140 Pearson’s
r in
nine mice; Hdh150 met
n = 49535
Pearson’s r in six mice
Figure 5—figure
supplement 1e
Mann-Whitney
test
LM WT vs LM Hdh150; MM WT vs MM Hdh150 p=0.04 WT n = 26126 Pearson’s r in
eight mice;
Hdh150 n = 58050 Pearson’s
r in
six mice; WT met n = 57140
Pearson’s r in nine mice;
Hdh150
met n = 49535 Pearson’s r in
six mice
Figure 5—figure
supplement 1f
Mann-Whitney
test
SS p=0.1, SL p=0.1, SM p=0.1, LL p=0.4, LM p=0.3, MM p=0.2 WT met n = 140467
distances
in nine mice; Hdh150 met
n = 117485 distances in six
mice
DOI: https://doi.org/10.7554/eLife.38744.011
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aggregates was observed, suggesting that MID1 and metformin indeed act through the same path-
way (Figure 4b, Figure 4—source data 1, Mann-Whitney test, control siRNA vs MID1 siRNA
p=0.009; control siRNA vs MID1 siRNA +metformin p=0.02).
We had shown previously that the MID1/PP2A/mTOR protein complex regulates the translation
efficiency of the human HTT mRNA in a repeat-dependent manner (Krauss et al., 2013). We there-
fore looked at a possible influence of metformin on the protein synthesis rate of mHTT exon one
protein using a previously described FRAP (Fluorescence recovery after photo bleaching) - based
assay that allows monitoring of protein translation rates in living cells (Krauss et al., 2013). We
a WT Hdh150
P
e
a
rs
o
n
's
 r 
1
4
0
1
2
0
1
0
0
8
0
6
0
4
0
2
0
0
140120100806040200
1
2
0
1
0
0
8
0
6
0
4
0
2
0
0
120100806040200
1.0
0.8
0.6
0.4
0.2
0
b
***
WT WT 
rand
Hdh150
P
e
a
rs
o
n
's
 r
 
0
0.1
0.2
0.3 * ***
Hdh150
 rand
c WT Hdh150
*
#
##
##
LL LM LH MM MH HH
Linear fit (WT) Linear fit (Hdh150)
WT rand
Linear fit (WT rand) Linear fit (Hdh150 rand)
WT Hdh150 Hdh150 randd e
0
1
2
3
4
5
Distance (µm)
P
e
a
rs
o
n
's
 r
 (
x
1
0
-2
)
20 80 140 200 260 >300
0
16
4
8
12
P
e
a
rs
o
n
's
 r
 (
x
1
0
-2
)
-0.4
-0.2
0
0.2
0.4
0.6
Distance (µm)
P
e
a
rs
o
n
's
 r
 (
x
1
0
-2
)
20 80 140 200 260 >300
****
Figure 2. Presymptomatic Hdh150 mice exhibit an increased synchronicity of cortical microcircuits. (a) Color-coded Pearson’s r matrices calculated from
representative recordings of WT (left) and Hdh150 (right) mice. Silent cells were excluded from the analysis. Right, color-coded scale of Pearson’s r
values. (b) Overall Pearson’s correlation coefficient (Pearson’s r) in WT (dark grey) and Hdh150 (red) mice for experimental (filled) and randomized
(open) raster data. Mann-Whitney test, WT vs. Hdh150 p<0.05; WT vs. WT rand p<0.0001; Hdh150 vs. Hdh150 rand p<0.0001 (c) Pearson’s r for
combinations of neuronal pairs (LL: low-low, LM: low-medium, LH: low-hyper, MM: medium-medium, MH: medium-hyper, HH: hyper-hyper) in WT (dark
grey) and Hdh150 (red) mice. * pairwise comparisons between a pair of WT and Hdh150 mice. # comparisons of functional subgroup pairs to the low-
low pair within the same genotype. The pairs involving hyperactive neurons could only be analyzed in Hdh150 mice. Mann-Whitney test, WT vs. Hdh150
mice: MM p<0.05 in Hdh150 mice; compared to LL: MM p<0.05, MH p<0.01, HH p<0.01 (d,e) Relationship between Pearson’s r and distance between
neuronal pairs in WT (black) and Hdh150 (red) mice (d) and randomized data (e). Lines represent the linear fit of WT and Hdh150 experimental data.
Two-way ANOVA (d) Genotype: p<0.0001 Distance: p=0.97, Interaction: p=0.3, (e) Genotype = 0.35, p=0.3, Interaction: p=0.8.
DOI: https://doi.org/10.7554/eLife.38744.012
The following source data and figure supplements are available for figure 2:
Source data 1. Numerical values of Figure 2 and associated supplement figures.
DOI: https://doi.org/10.7554/eLife.38744.015
Figure supplement 1. Randomization of experimental data to assess specific network synchronicity.
DOI: https://doi.org/10.7554/eLife.38744.013
Figure supplement 2. Presymptomatic Hdh150 mice did not exhibit alteration of mitochondria respiration.
DOI: https://doi.org/10.7554/eLife.38744.014
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detected a clear reduction in the protein synthesis rate of a GFP-Htt fusion protein carrying 49
repeats in the metformin-treated samples in a concentration-dependent manner in primary neurons
(Figure 4c, Figure 4—source data 1, RM two-way ANOVA p=0.008). This effect was confirmed in
N2A cells (Figure 4—figure supplement 1a, Figure 4—source data 1, RM two-way ANOVA
p=0.03). To further support the contribution of the MID1/PP2A/mTOR protein complex and PP2A
activity to this effect, the GFP-Htt transfected cells were subsequently either (i) mock treated, (ii)
treated with only metformin, (iii) treated with ocadaic acid (OA), or (iv) co-treated with metformin
and OA. OA is an inhibitor of PP2A activity. As expected, OA significantly increased translation rates
of the GFP-Htt reporter mRNA and metformin did not have a reducing effect on the translation rates
in cells co-treated with OA suggesting that indeed the metformin effect is mediated by PP2A activity
(Figure 4d, Figure 4—source data 1, RM two-way ANOVA p=0.002).
To analyze metformin effects on early signs of pathology in vivo, VFDO Hdh150 mice were fed
with, or without 5 mg/ml metformin in the drinking water. Metformin did not significantly reduce
drinking volume (Figure 4—figure supplement 1b, Figure 4—source data 1, RM two-way ANOVA
not significant, see Table 1 for p-values). After 3 weeks of treatment, we looked at phosphorylation
patterns of the PP2A/mTOR target S6 and the amount of mHtt protein relative to wild-type Htt in
whole brain tissue. The metformin-treated group showed a significant reduction of S6 phosphoryla-
tion suggesting an increase in PP2A activity (Figure 4e and f, Figure 4—source data 1, unpaired
t-test p=0.05). At the same time, a slight tendency (not significant) of reduced mHtt was detected
suggesting that metformin has an influence on mHtt expression (Figure 4—figure supplement 1c
and d, Figure 4—source data 1, unpaired t-test not significant, see Table 1 for p-values). A signifi-
cant reduction of mHtt expression, however, became clearly visible after 11 weeks of treatment in
cortical tissue (Figure 4g–j, Figure 4—source data 1, unpaired t-test, mHtt/wtHtt p=0.05, mHtt/
Gapdh p=0.002, wtHtt/Gapdh p=0.9).
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Figure 3. Presymptomatic VFDO Hdh150 mice exhibit anxiolytic behavior. (a) Representative travel pathways of WT (left) and presymptomatic Hdh150
(right) mice analyzed in a 5 min open field test. (b) Increased explorative behavior of Hdh150 animals compared to the WT mice. Mann-Whitney test,
p<0.05.
DOI: https://doi.org/10.7554/eLife.38744.016
The following video, source data, and figure supplement are available for figure 3:
Source data 1. Numerical values of Figure 3 and associated supplement figures.
DOI: https://doi.org/10.7554/eLife.38744.018
Figure supplement 1. Presymptomatic VFDO Hdh150 mice did not exhibit deficit in visual discrimination test and explorative behavior in novel object
recognition test.
DOI: https://doi.org/10.7554/eLife.38744.017
Figure 3—video 1. Example of visual discrimination task performed by a trained mouse, real time.
DOI: https://doi.org/10.7554/eLife.38744.019
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Figure 4. Metformin reduces translation rates of mutant HTT through MID1/PP2A protein complex in vitro and decreases both S6 phosphorylation and
mutant Htt protein load in Hdh150 animals. (a) FLAG-HTT detected on a filter retardation assay after treatment with and without 1 mM and 2.5 mM
metformin. Quantification on right panel. Mann-Whitney test, control vs. 1 mM metformin p=0.08; control vs. 2.5 mM metformin, p<0.05. (b) Stable cell
line expressing FLAG-HTT exon1 with 83 CAG repeats transfected with MID1-specific siRNAs or control siRNAs in the presence or absence of 2.5 mM
Figure 4 continued on next page
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Metformin reverses signs of Huntington’s disease pathology
Our data suggest metformin as a promising molecule to interfere with VFDO Huntington’s disease
biochemical and cellular pathological changes. We initially used a C. elegans model of polyQ-medi-
ated diseases to test whether metformin effectively ameliorates disease symptoms in an easily con-
trollable model with short lifespan. The C. elegans worms carry a transgene encoding YFP-tagged
Q40 polypeptide in body wall muscle cells (Morley et al., 2002). Adult Q40::YFP nematodes exhibit
intracellular aggregates of polyglutamine-containing protein and develop progressive paralysis over
time, which is reflected in significantly reduced motility. We counted aggregates in metformin-
treated and untreated nematodes. Moreover, we assessed their motility in a liquid thrashing experi-
ment, in which worms are placed in liquid and the frequency of lateral swimming (thrashing) move-
ment is analyzed as a measure of motility. We found that 5 days of metformin treatment reduced
the number of intracellular inclusion bodies significantly and rescued motility impairment (Figure 4—
figure supplement 2a and b, Figure 4—source data 1, Mann-Whitney, p<0.0001). Since bacteria
can metabolize metformin (Cabreiro et al., 2013), we confirmed the results on heat-inactivated
OP50 bacteria (Figure 4—figure supplement 2c, Figure 4—source data 1, Mann-Whitney test,
control vs 5 mM metformin p=0.008, control vs 10 mM metformin p<0.0001). siRNA-mediated
knock-down of arc-1, the C.elegans MID1 homolog, leads to a reduction of inclusion bodies and
improved motility similar to the metformin effects (Figure 4—figure supplement 2d and e, Fig-
ure 4—source data 1, Mann-Whitney test, p<0.0001) and confirms that the MID1/PP2A/mTOR pro-
tein complex underlies metformin effects.
We then asked whether metformin could rescue the altered cortical activity in vivo in Hdh150
mice. Metformin treatment did not affect the density of OGB-1 stained cells (Figure 5—figure sup-
plement 1a,b, Figure 5—source data 1, WT: 1413 ± 74 cells/mm2 (n = 11 mice), Hdh150: 1456 ± 90
cells/mm2 (n = 10 mice), WT met: 1351 ± 65 cells/mm2 (n = 9 mice) and Hdh150 met: 1448 ± 60
cells/ mm2 (n = 6 mice), unpaired t-test, not significant, see Table 1 for p-values). Notably, 3
weeks of metformin treatment in the drinking water completely restored the proportion of active
cells (Figure 5b, Figure 5—source data 1, Hdh150: 77.2 ± 3.5% (n = 6 mice), Hdh150 met: 64.4 ±
4.1% (n = 6 mice), Mann-Whitney test p<0.05) and the average frequency of Ca2+ transients
(Figure 5a,c, Figure 5—source data 1, Hdh150: 1.2 ± 0.1 trans/min (n = 6 mice), Hdh150 met: 0.7 ±
0.06% (n = 6 mice), Mann-Whitney test p<0.05). The individual traces of treated Hdh150 animals
were indistinguishable from untreated WT animals (Figure 5a, Figure 5—figure supplement 1c).
Figure 4 continued
metformin. FLAG-HTT detected on a filter retardation assay. Efficiency of the knock-down including Actin as a loading control is shown on a western
blot (left panel). Quantification of filter retardation assay on right panel. Mann-Whitney test, control siRNA vs. MID1 siRNA p<0.01; control siRNA vs.
MID1 siRNA + metformin p<0.05. (c) Protein translation rate of GFP-tagged mutant Htt exon1 (49 CAG repeats) in primary cortical neurons measured in
a FRAP-based assay, over a time frame of 4 hr. Lines show the GFP-signal intensity over time in mock-treated (control) and metformin-treated (1 mM
and 2.5 mM) cells. Lines represent means, shadowed areas standard deviations. Repeated measures two-way ANOVA, treatment p<0.01, time
p<0.0001; interaction p<0.0001. (d) Protein translation rate measured in a FRAP-based assay (see c). Lines show the GFP-signal intensity over time in
mock-treated (control), metformin-treated (2.5 mM), ocadaic acid (OA)-treated and metformin +OA-treated cells. Shadowed areas show SEM. Repeated
measures two-way ANOVA, treatment p<0.01, time p<0.0001, interaction p<0.0001. (e) Transgenic Hdh150 mice received metformin-containing water
(5 mg/ml, Hdh150 +metformin) or pure water (Hdh150) over a period of 3 weeks. Whole brain lysates were analyzed for the phosphorylation of S6, the
expression of total S6, mHtt and wtHtt on western blots. Representative western blots are shown. (f) Quantification of pS6 relative to S6. Unpaired
t-test, p<0.05. (g) mHtt and wt Htt proteins of prefrontal cortex lysates analyzed on western blots after 11 weeks of treatment with metformin (5 mg/ml,
Hdh150 +metformin) or pure water (Hdh150). Representative western blots are shown. (h) Quantification of mHtt relative to wtHtt. Treatment of 5 mg/
ml metformin in the drinking water showed a significant reduction of mHtt protein compared to water control treatment. Unpaired t-test p <<0.05 (i)
Quantification of mHtt relative to Gapdh. Unpaired t-test, p<0.01. (j) Quantification of wtHtt relative to Gapdh. Unpaired t-test, p=0.88.
DOI: https://doi.org/10.7554/eLife.38744.020
The following source data and figure supplements are available for figure 4:
Source data 1. Numerical values of Figure 4 and associated supplement figures.
DOI: https://doi.org/10.7554/eLife.38744.023
Figure supplement 1. Metformin reduces mutant Htt protein translation and does not change drinking behavior of Hdh150CAG animals.
DOI: https://doi.org/10.7554/eLife.38744.021
Figure supplement 2. Metformin treatment rescues motility impairment in a C.elegans model.
DOI: https://doi.org/10.7554/eLife.38744.022
Arnoux et al. eLife 2018;7:e38744. DOI: https://doi.org/10.7554/eLife.38744 14 of 32
Research article Neuroscience
Hdh150 metWT met b
50s
n1 n1
n2
n3
n4
n5
n6
n7
n8
n9
n10
n2
n3
n4
n5
n6
n7
n8
n9
n10
e f
a
c
WT Hdh150 WT met Hdh150 met
%
 o
f 
a
c
ti
v
e
 c
e
lls
WT
 
Hdh150 WT 
met
 
Hdh150 
met 
0
20
40
60
80
100 *
WT
 
Hdh150 WT 
met
 
Hdh150 
met 
0
0.4
0.8
1.2
1.6
2
fr
e
q
u
e
n
c
y
 (
tr
a
n
s
/m
in
)
**
** **
gHyper
d
0
1
2
3
4
5
Distance (µm)
P
e
a
rs
o
n
's
  
r 
(x
1
0
-2
)
40 80 120 160 200 240 280 >300WT
 
Hdh150 WT 
met
 
Hdh150 
met 
P
e
a
rs
o
n
's
  
r 
0
0.1
0.2
0.3 * **
**
h i
31%
69%
Medium
Low 
0%
W
T
 m
e
t
H
d
h
1
5
0
 m
e
t
28%
72%
0%
Hyper
Low 
Medium
W
T
 m
e
t
Open field
H
d
h
1
5
0
 m
e
t
*
*
WT WT metHdh150 Hdh150 
met
0
5
10
15
20
25
30
35
****
%
 T
im
e
 i
n
 c
e
n
te
r
*
C
u
m
u
la
ti
v
e
 p
ro
b
a
b
ili
ty
 (
%
)
0
20
40
60
80
100
WT Hdh150 WT met Hdh150 met
frequency (trans/min)
>4.84.20.6 1.5 2.3 3.3
Low Medium Hyper
Figure 5. Metformin treatment reverses pathological neuronal network activity and behavioral abnormalities in presymptomatic VFDO Hdh150 mice.
(a) Representative traces of spontaneous Ca2+ transients of 10 neurons recorded in vivo in WT and Hdh150 mice after metformin treatment. Vertical
scale bar: 40% dF/F. (b) Relative proportion of spontaneously active neurons in WT (dark grey), Hdh150 (red), WT metformin-treated (light grey) and
Hdh150 metformin-treated (light red) mice. Mann-Whitney test, WT vs. Hdh150, p<0.05; Hdh150 vs. Hdh150 met, p<0.05; Hdh150 vs. WT met, p<0.05.
Figure 5 continued on next page
Arnoux et al. eLife 2018;7:e38744. DOI: https://doi.org/10.7554/eLife.38744 15 of 32
Research article Neuroscience
Importantly, in these experiments, metformin acts specific on dysregulated network components.
Only the AUC of calcium transients was slightly yet significantly affected in WT mice which might be
due to an increase of baseline calcium concentration induced by the activation of MID1/PP2A/mTOR
signaling pathway (Figure 5—figure supplement 1c, Figure 5—source data 1). One of the hall-
marks of the VFDO Hdh150 mice was the distinct functional subgroup of hyperactive neurons (Fig-
ure 1). We thus assessed the effect of metformin treatment on the relative proportions of low,
normal and hyperactive subgroups. Treatment with metformin in Hdh150 mice led to the complete
abolishment of the hyperactive subgroup (Figure 5d, Figure 5—source data 1, two-way ANOVA
p<0.0001 and Figure 5e, Figure 5—source data 1, Chi-square test not significant, see Table 1 for
p-values) and restored the relative proportion of functional subgroups. The spatial distribution of
functional subgroups remained unchanged by metformin treatment (Figure 5—figure supplement
1f, Figure 5—source data 1, Mann-Whitney test, not significant, see Table 1 for p-values). This
complete restoration of dysregulated microcircuit activity was also evident in the cumulative fre-
quency distribution (Figure 5d, Figure 5—source data 1) and all other network measures found to
be aberrant in young Hdh150 animals, such as synchronicity (Figure 5f and g, Figure 5—figure sup-
plement 1d–e, Figure 5—source data 1).
Accompanying the network dysfunction, we observed anxiolytic behavior in the VFDO Hdh150
mice (see Figure 3a–b). Treatment with metformin fully reversed the anxiolytic behavior (Figure 5h
and i, Figure 5—source data 1, Mann-Whitney test, WT vs Hdh150 p=0.002, Hdh150 vs Hdh150
met p=0.002, Hdh150 vs WT met p=0.03, WT vs Hdh150 met p=0.8).
In conclusion, our data suggest that metformin, by interfering with the translation rate of mHtt
protein, reduces protein load in cell culture and in vivo and reverses early Huntington’s disease-
related network dysregulations as well as anxiety-related behavioral aberrations in mice. Further-
more, usage of metformin in adult C. elegans, a model of polyQ disease, also significantly influences
inclusion bodies formation and motility.
Discussion
Here, we have identified a dysregulation of spontaneous neuronal activity in the visual cortex in
a very early stage of a mouse model of Huntington’s disease that corresponds to a very early
stage in the premanifest stage in Huntington’s disease mutation carriers (Figure 1a,b), which
might indeed be a distinct pathological disease stage which is very far from disease onset
(VFDO). Correspondingly, the visual cortex is one of the first structures affected in patients
(Labuschagne et al., 2016; Dogan et al., 2013). This dysregulation is characterized by an
Figure 5 continued
(c) Significant reduction in the spontaneous Ca2+ transient frequency to WT levels in Hdh150 mice after metformin treatment (red vs. light red). Mann-
Whitney test, WT vs. Hdh150, p<0.01; Hdh150 vs. Hdh150 met, p<0.01; Hdh150 vs. WT met, p<0.01. (d) Cumulative frequency distributions of Ca2+
transients in WT (dark grey), Hdh150 (red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. Top, color-coding of
active neurons by frequency. Two-way ANOVA test, Group: p<0.0001; Time: p<0.0001; Interaction: p<0.0001. (e) Pie charts showing the relative
proportion of low (blue), medium (orange) and hyperactive (red) neurons in layer 2/3 of the visual cortex in WT (top) and Hdh150 (bottom) mice after
metformin treatment. Chi-square test, p=0.62, Chi-square = 0.24. (f) Comparison of Pearson’s r between a pair of neurons in WT (dark grey), Hdh150
(red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. Mann-Whitney test, WT vs. Hdh150, p<0.05, Hdh150 vs.
Hdh150 met, p<0.01, Hdh150 vs. WT met, p<0.01. (g) Relationship between pairwise Pearson’s r and pairwise distance in metformin-treated WT (light
grey) and Hdh150 (light red) mice. Two-way ANOVA test, group p<0.0001; Distance p=0.09; Interaction p<0.001. (h) Representative travel pathways of a
metformin-treated WT (left) and pre-symptomatic Hdh150 (right) mice analyzed in a 5 min open-field test. (i) Decrease in the explorative behavior of
metformin-treated Hdh150 animals. Mann-Whitney test, WT vs. Hdh150, p<0.01; Hdh150 vs. Hdh150 met, p<0.001; Hdh150 vs. WT met, p<0.05; WT vs.
Hdh150 met, p=0.8.
DOI: https://doi.org/10.7554/eLife.38744.024
The following source data and figure supplement are available for figure 5:
Source data 1. Numerical values of Figure 5 and associated supplement figures.
DOI: https://doi.org/10.7554/eLife.38744.026
Figure supplement 1. Metformin treatment does not affect cell density or Ca2+ transient dynamics
DOI: https://doi.org/10.7554/eLife.38744.025
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increase in cortical network activity patterns, the emergence of a functional subgroup of hyper-
active neurons, and enhanced synchronicity. Overall visual cortex functioning seems to be pre-
served at this early time point of Huntington’s disease course. Network changes are
accompanied by subtle behavior alterations including an anxiolytic phenotype, suggesting that at
least part of the brain-wide circuitry exhausted its compensational reserve. Anxiety-related
abnormalities including anxiolytic behavior have previously been described in the preclinical
phase in several other rodent Huntington’s disease models ((Nguyen et al., 2006), reviewed in
[Pouladi et al., 2013]). So far, changes described here represent the earliest identified abnor-
malities in cortical pathophysiology and behavior in heterozygous Hdh150 animals, which closely
resemble the human disease (Lin et al., 2001; Heng et al., 2007; Brooks et al., 2012; Tallak-
sen-Greene et al., 2005). Furthermore, we show that the type II diabetes drug metformin inhib-
its the translation of mHtt protein and thereby decreases mHtt protein load in vitro and in vivo.
Promisingly, this leads to a complete restoration of VFDO network activity patterns as well as
behavior abnormalities under chronic metformin therapy.
Our data report primal changes in cortical network function in the VFDO stage of Huntington’s
disease. A recognition of the network as a pathophysiological entity has recently been suggested in
the context of Alzheimer’s disease (Busche et al., 2008; Iaccarino et al., 2016). Moreover, focus has
shifted away from the mechanisms accompanying neuronal and network degeneration and instead
moved toward small and subtle functional changes at very early stages of the disease when irrevoca-
ble damage to the network has not yet occurred (Busche and Konnerth, 2016). Indeed, hyperactive
neurons are associated with both advanced and early stages of Alzheimer’s disease, independent of
plaque formation (Busche et al., 2012; Busche et al., 2008). In addition, evidence points toward
hyperactive neurons preventing the cortex-wide propagation of slow oscillations in early Alzheimer’s
disease (Busche et al., 2015).
We here describe a similarly distinct hyperactive phenotype in very early stages of Hunting-
ton’s disease. We conclude that neuronal hyperactivity may be a principle mechanism that devel-
ops early not only in Alzheimer’s disease but also in other neurodegenerative diseases. Thus,
the notion of early network dysregulation as a therapeutic target may have broad implications.
Similar to early stages of Alzheimer’s disease hyperactive neurons in Hdh150 animals emerge in
the absence of aggregate formation. Also hyperactive cells do not cluster, and reactive astrocytes or
cells with activated caspase-3 as a marker of early apoptosis are not found in these early stages of
Huntington’s disease. Furthermore, cortical neurons did not exhibit metabolic dysregulation as mea-
sured in a mitochondrial respiration assay. Therefore, we may postulate that the cortex merely
responds to early pathophysiological events already commencing in subcortical regions, e.g. the stri-
atum. This is well in line with the current emerging hypotheses of disease progression in Alzheimer’s
disease. Young Alzheimer’s disease animals develop hyperactivity in a plaque-independent fashion
first in the hippocampus (possibly due to higher vulnerability of the hippocampus in Alzheimer’s dis-
ease), followed by a similar hyperactivity pattern in the cortex later in the disease process
(Busche et al., 2012; Busche et al., 2008). Furthermore, in Alzheimer’s disease patients, degenera-
tion of cortical projection targets of the hippocampus is associated with hippocampal hyperactivity
indicating a connectivity-based spread of network dysregulations eventually leading to neurodegen-
eration (Putcha et al., 2011). Our data indeed suggest an altered activity in subcortical drivers, since
unspecific alteration of excitability in individual neurons is unlikely to lead to an increase in synchro-
nicity, but rather would result in a random increase in firing.
Our data was collected at very early stages of the disease in the Hdh150 mouse model, which
corresponds to the VFDO stage in Huntington’s disease patients. The importance of expression of
mutant Htt protein during very early phases for disease development has been demonstrated in the
BACHD:CAG-CreERT2 mouse (Molero et al., 2016). With the help of tamoxifen treatment expression
of mutant Htt was turned off early postnatally. Still the typical symptoms of Huntington’s disease at
three and nine months of age were observed in the animals. We conclude that only at the VFDO
stages, when cellular and network degeneration have not yet been established, preventive strategies
will be most effective; only then can we still rescue small homeostatic shifts, prevent spreading and
potentially stabilize network function.
Phenotype reversal could be demonstrated in a tetracyclin-dependent conditional mouse model
for Huntington’s disease. Both neuropathological findings and behavior aberrations were found to
disappear when mHtt protein production was stopped through a tet-off regulation mechanism in the
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adult animal (Yamamoto et al., 2000). Additional support for the beneficial effect of suppression of
aberrant protein production on the Huntington’s disease phenotype stems from several studies with
RNA interference (siRNA), or antisense oligonucleotides showing that gene suppression reducing
mHtt protein load by 40% or more, is sufficient to significantly ameliorate the Huntington’s disease
phenotype (HD iPSC Consortium, 2017; Harper et al., 2005; Keiser et al., 2016; Stanek et al.,
2014). These studies have demonstrated, that (i) the earlier suppression takes place the more robust
and beneficial effects on behavior phenotypes are [reviewed in (Keiser et al., 2016)] and (ii) that
even transient suppression of Htt protein during early disease stages was sufficient to obtain long-
term effects on the disease phenotype lasting for months, far beyond the treatment period (Lu and
Yang, 2012; Kordasiewicz et al., 2012).
However, developing siRNA and antisense oligonucleotides technologies into therapeutics for
clinical use is difficult and a long way to go. Difficulties here include toxicity and modes of delivery:
so far oligonucleotides have to be regularly injected into the cerebrospinal fluid, which is a huge
effort for patients and physicians. Furthermore, a short N-terminal fragment of the mHtt protein,
mHttexp1p, that is produced by incomplete exon one splicing and a short poly-adenylated mRNA in
several animal models as well as in Huntington’s disease patients rather than full-length mHtt protein
was found to be particularly pathogenic. Its occurrence correlates well with age of onset and severity
of the disease. This short mRNA is difficult to target by oligonucleotide strategies (Neueder et al.,
2017; Sathasivam et al., 2013). We show here that a well-known, widely used, orally delivered small
compound, metformin, suppresses mHtt production by targeting both, full-length and mHttex1p, in
vitro and in vivo and thereby significantly reduces mHtt protein load, which makes it a very promis-
ing candidate for chronic early onset Huntington’s disease therapy.
Metformin is an FDA-approved, inexpensive biguanide that has been used in patients with Type II
diabetes for decades and is under discussion for cancer preventive therapy (Demir et al.,
2014; Micic et al., 2011). Very recently, metformin has been shown to rescue core phenotypic fea-
tures in a mouse model for fragile X-syndrome, a neurodevelopmental disorder, by normalizing ERK
signalling (Gantois et al., 2017).
Metformin had been brought in as a promising compound in Huntington’s disease previously.
It has been found to protect cells from the toxicity of mutant Huntingtin protein in a cell culture
model (Jin et al., 2016). In a study on R6/2 animals, a very aggressive model for Huntington’s
disease, Ma and colleagues had found a significant effect on survival rates and hind clasping in
male animals only when given metformin in the drinking water starting from week 5 (Ma et al.,
2007). In relation to the phenotype in the R6/2 animals that develops severe aberrations from 4
weeks on this is a late time point and would be placed in the motor phase stage when pro-
jected to the phenotypic time line given in Figure 1a. We hypothesize here that preventive
treatment at a very early stage is important to substantially and stably influence the disease.
This is in agreement with observations in a mouse model for spinocerebellar ataxia I, another
neurodegenerative disease based on CAG expansion and studies with antisense oligonucleotides
in a Huntington’s disease model. Both studies show that gene suppression has more stable
effects on the phenotype when performed early enough (Kordasiewicz et al., 2012;
Rubinsztein and Orr, 2016; Zu et al., 2004). In line with that only two phenotypic features had
been found to react on late metformin treatment- survival rates and frequency of clasping- in
the R6/2 animals. Also and again as expected, effect size on animal survival was quite small
(p=0.02). Gender differences in response rate seen in this study can possibly be explained by
gender differences in disease development and progression at the motor stage, which had been
observed in several mouse models (Menalled et al., 2009). When disease progression differs,
differences in blood brain barrier permeability can be expected (reviewed in [Sweeney et al.,
2018]) which then is likely to lead to gender specific variation in bioavailability of metformin in
the brain. In contrast to this study we here show that in vivo metformin has highly significant
effects (p=0.03 to p<0.0001) already on primal changes in the very early, VFDO phases of Hun-
tington’s disease making metformin a promising compound for the development of a therapeu-
tic scheme that is based on early prevention of pathology development. While we focused on
male mice in this study, to reduce physiological variability due to hormone fluctuations, at the
VFDO stage brain barrier changes are not expected to influence bioavailability of metformin.
Metformin was suggested to lead, through AMPK activation, to a reduction of mHtt aggregates
in vitro (Walter et al., 2016; Va´zquez-Manrique et al., 2016). In our previous work, however, we
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have shown that in cortical neurons metformin does not induce phosphorylation of the AMPK target
ACC at all and only when given chronically it induces phosphorylation of AMPK itself in vitro. When
giving 5 mg/ml metformin in the drinking water for 16 – 24 days to wildtype animals, while phos-
phorylation of S6 is significantly reduced, AMPK phosphorylation does not change in whole brain
extracts (Kickstein et al., 2010). This indicates that AMPK activation is likely to depend on the dose.
In WT animals as in preclinical Huntington’s disease animals the blood-brain barrier is intact, which
limits bioavailability of metformin in the brain. Metformin concentrations needed to influence
mTOR/PP2A activity seem to be significantly lower than those needed to influence AMPK activity.
Like in the Kickstein et al. paper, in the present study, we used 5 mg/ml metformin in the drinking
water, a concentration at which AMPK activation is not expected, but as we show here in the
Hdh150 animals, metformin has a significant effect on the phosphorylation of the mTOR/PP2A target
S6.
The effect of Htt loss on brain function is still under debate. SiRNA studies suggest that postnatal
reduction of endogenous Htt protein is well tolerated (summarized in [Keiser et al., 2016]). How-
ever, conditional knock-out animals with a perinatal loss of around 40% of Htt protein in the fore-
brain show a neurodegenerative phenotype (Dragatsis et al., 2000). Likewise, depletion of Htt
protein in the adult brain leads to progressive behavior deficits (Dietrich et al., 2017). We demon-
strate here that metformin has a very specific effect on the expression of mHtt protein only, leaving
wild-type Htt that is produced from the non-mutated allele in dominant Huntington’s disease
untouched (Figure 4). This makes metformin the only compound available at present with a specific
effect on only mutant but not wild-type Htt protein.
In support of an effect of metformin in Huntington’s disease patients an in silico comparison of
cognitive performance of Huntington’s disease patients treated with metformin was performed. In
this study, using the Enroll patient cohort, it was shown that diabetic Huntington’s disease patients
in the manifest stage treated with metformin had a better cognitive performance than Huntington’s
disease patients not treated with metformin (Herva´s et al., 2017).
Our data indicate that metformin treatment reverses all cortical network dysregulations in
vivo in the premanifest VFDO Hdh150 mice including functional sub-group distribution, fre-
quency and synchronicity. Regaining network stability shows promise for ameliorating the molec-
ular pathophysiology, probably by activating intrinsic repair mechanisms as shown in the context
of Alzheimer’s disease (Iaccarino et al., 2016; Keskin et al., 2017). Following this network-cen-
tered view, restoration of network functions might also prevent secondary damage to the neuro-
nal microcircuit. We therefore propose a shift in experimental treatment strategies: rather than
exploring single pathways for target, we might also consider re-balancing network function in
the VFDO stages of the disease.
Taken together, our data provide evidence for the existence of a pathophysiological entity very
far from onset of the manifest disease (VFDO) characterized by early homeostatic changes of net-
work activity and, associated with that, subtle behavior alterations. The data also strongly support
the observation that, similar to humans, the disease in mice develops over a long period of time.
This provides an early critical window of vulnerability and gives opportunities for early therapeutic
interference with disease development. So far, all attempts to develop a causative therapy for Hun-
tington’s disease have been unsuccessful [summarized in (Crook and Housman, 2011; Cla-
bough, 2013)]. In terms of therapeutic intervention, consideration should be given to a chronic
treatment of mutation carriers, which covers the critical windows of vulnerability, as early as in the
VFDO stages. Such a strategy avoids delaying intervention until clinical signs of the disease are evi-
dent, implying that substantial brain damage has already occurred. Our data suggest that metformin
has the potential to reduce mHtt protein load and to substantially influence the early development
of pathology and, as seen in a C. elegans model, protein aggregation and movement aberrations
which are pathognomonic for later disease stages. It is an inexpensive substance, well known in
long-term clinical usage and has a defined, relatively benign spectrum of side effects. Prescription to
mutation carriers from young adulthood on (or even earlier) is possible and will cover these newly
discovered critical windows of opportunity for therapy.
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Materials and methods
Key resources table
Reagent type
(species)
or resource Designation Source or reference Identifiers
Additional
information
Genetic reagent
(C.elegans)
C.elegans strain AM141,
genotype rmIs133
University
of Minnesota
AM141 (WormBase ID)
RRID:WB-STRAIN:AM141
Genetic reagent
(M. Musculus)
Hdh150 Jackson
Laboratory
#004595
RRID:IMSR_JAX:004595
Only males
were used
Cell line
(H. sapiens)
HEK 293T/17 Scherzinger et al.
(1997)
CRL-11268
RRID:CVCL_1926
Cell line
(M. Musculus)
Neuro-2A ATCC ATCC CCL131
RRID:CVCL_0470
Cell line
(M. Musculus)
primary cortical
neurons
isolated from
NMRI (Janvier)
Transfected
construct
pEGFP-C1-
Httex1
Krauss et al., 2013 Self-cloned
Antibody rabbit anti-
activated-caspase-3
Cell signaling 9661
RRID:AB_2341188
1 to 500
Antibody mouse anti-NeuN Millipore MAB377
RRID:AB_2298772
1 to 500
Antibody rabbit anti-GFAP Dako Z0334
RRID:AB_10013382
1 to 1500
Antibody rabbit anti-Htt Abcam ab109115
RRID:AB_10863082
WB: 1:850, IHC:
1:200
Antibody Alexa 546 goat
anti-rabbit
Invitrogen A11035
RRID:AB_143051
1 to 300
Antibody Alexa 647 goat
anti-mouse
Invitrogen A21235
RRID:AB_141693
1 to 300
Antibody Cy2 donkey
anti-rabbit
Jackson Immuno Research 711-225-152 RRID:AB_2340612 1 to 300
Antibody Alexa 488 goat
anti-rabbit
Life technologies A11008 RRID:AB_143165 1 to 200
Antibody anti-FLAG M2-
Peroxidase
Sigma-Aldrich A8592 RRID:AB_439702 1 to 3000
Antibody rabbit anti-actin Sigma-Aldrich A2066
RRID:AB_476693
1 to 2000
Antibody rabbit anti-pS6 Cell signaling 2215
RRID:AB_2630325
1 to 2000
Antibody mouse anti-GAPDH Abcam ab8245
RRID:AB_2107448
1 to 2000
Antibody HRP-anti-mouse Dianova 115-035-072
RRID:AB_2338507
1 to 6000
Antibody HRP-anti-rabbit Dianova 305-036-003
RRID:AB_2337936
1 to 6000
Antibody goat anti-rabbit IgG,
AlexaFluor 488
conjugate
Life technologies A11008
RRID:AB_143165
1 to 200
Sequence-
based reagent
primers 5’-CCC ATT
CAT TGC CTT GCT
GCT AGG-3’ and 5’-CCT
CTG GAC AGG GAA CAG
Sigma-Aldrich custom
Sequence-
based reagent
siRNA AATTGACAGAG
GAGTGTGATC
Qiagen custom
Sequence-
based reagent
siRNA CACCGCAUCCUAGUAUCACACTT Qiagen custom
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers
Additional
information
Sequence-
based reagent
siRNA CAGGAUUACAACUUUUAGGAATT Qiagen custom
Sequence-
based reagent
siRNA TTGAGTGAG
CGCTATGACAAA
Qiagen custom
Sequence-
based reagent
siRNA AAGGTGAT
GAGGCTTCGCAAA
Qiagen custom
Sequence-
based reagent
siRNA TAGAACGT
GATGAGTCATCAT
Qiagen custom
Sequence-
based reagent
non siRNA AATTCTCCG
AACGTGTCACGT
Qiagen custom
Chemical
compound, drug
Hoechst33342 Sigma-Aldrich B2261
CHEBI:51232
1 to 1000
Chemical
compound, drug
Fluoromount Sigma-Aldrich F4680
Chemical
compound, drug
Fluoroshield
Mounting Medium
Abcam ab104135
Chemical
compound, drug
PBS tabletts gibco 18912–014
Chemical
compound, drug
Triton-X Roth 6683.1
CHEBI:9750
0.3%
Chemical
compound, drug
Tween20 Roth 9127.1 0.1%
Chemical
compound, drug
Triton X-100 Sigma-Aldrich T8787 CHEBI:9750 1 – 0.1%
Chemical
compound, drug
natural donkey
serum
Abcam ab7475
RRID: AB_2337258
4 – 2%
Chemical
compound, drug
natural goat
serum
Abcam ab7481
RRID:2532945
4 – 2%
Chemical
compound, drug
natural sheep
serum
Abcam ab7489
RRID: AB_2335034
20%
Chemical
compound, drug
xylocaine AstraZeneca PUN080440 2%
Chemical
compound, drug
isoflurane AbbVie 8506 CHEBI:6015 1–1.55%
Chemical
compound, drug
PBS Life technologies 18912–014 1 M
Chemical
compound, drug
paraformaldehyde Life technologies 15710
CHEBI:31962
diluted to
4%
Chemical
compound, drug
Oregon-Green
BAPTA1 AM
Molecular probes O6807 1 mM
Chemical
compound, drug
EGTA Sigma-Aldrich E4378
CHEBI:30740
0.5 mM
Chemical
compound, drug
MgCl2 Sigma-Aldrich M2670
CHEBI:86345
3 mM
Chemical
compound, drug
K-lactobionate Sigma-Aldrich L2398
CHEBI:55481
60 mM
Chemical
compound, drug
Taurine Sigma-Aldrich T0625
CHEBI:15891
20 mM
Chemical
compound, drug
KH2PO4 Sigma-Aldrich P5655
CHEBI:63036
10 mM
Chemical
compound, drug
HEPES Sigma-Aldrich H3375
CHEBI:42334
20 mM
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers
Additional
information
Chemical
compound, drug
Sucrose Sigma-Aldrich S0389
CHEBI:17992
110 mM
Chemical
compound, drug
BSA Sigma-Aldrich A6003 1 g/L
Chemical
compound, drug
Malate Sigma-Aldrich M1000
CHEBI:6650
2 mM
Chemical
compound, drug
Pyruvate Sigma-Aldrich P2256
CHEBI: 50144
10 mM
Chemical
compound, drug
Glutamate Sigma-Aldrich G1626
CHEBI:64243
20 mM
Chemical
compound, drug
ADP Sigma-Aldrich A2754
CHEBI:16761
5 mM
Chemical
compound, drug
Succinate Sigma-Aldrich S2378
CHEBI:63686
10 mM
Chemical
compound, drug
FCCP Sigma-Aldrich C2920
CHEBI:75458
0.2 mM
Chemical
compound, drug
Rotenone Sigma-Aldrich R8875
CHEBI:28201
0.1 mM
Chemical
compound, drug
Antimycin A Sigma-Aldrich A8674
CHEBI:22584
2 mM
Chemical
compound, drug
MgSO4 Sigma-Aldrich 203726
CHEBI:32599
Chemical
compound, drug
NaCl Sigma-Aldrich S3014
CHEBI:26710
Chemical
compound, drug
Na2HPO4 Sigma-Aldrich S3264
CHEBI:34683
Chemical
compound, drug
oligofectamine Thermo-Fisher 12252–011 0.2%
Chemical
compound, drug
metformin MP Biomedicals 157805
CHEBI:6802
5 mg/ml
Chemical
compound, drug
urea Roth 2317.3
CHEBI:16199
48%
Chemical
compound, drug
Tris Roth 4855.2
CHEBI:9754
15 mM
Chemical
compound, drug
Glycerin Roth 3783.1
CHEBI:17754
8.7%
Chemical
compound, drug
SDS Roth 2326.1
CHEBI:8984
1%
Chemical
compound, drug
mercaptoehanol Roth 4227.3
CHEBI:41218
1%
Chemical
compound, drug
protease
inhibitors
Roche 04 693 116 001 1 tablet
per 50 ml
Chemical
compound, drug
Phosstop Roche 04 906 837 001 2 tablets
per 10 ml
Software,
algorithm
GraphPad
Prism
GraphPad
Prism
RRID:SCR_002798 http://www.
graphpad.com/
Software,
algorithm
Igor Pro
6.22 – 6.37
Wavemetrics RRID:SCR_000325 http://www.wave
metrics.com
/products/igorpro
/igorpro.htm
Software,
algorithm
MATLAB R2011a Mathworks RRID:SCR_001622 https://www.math
works.com
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers
Additional
information
Software,
algorithm
Code use for
Calcium
transient
analysis
this paper the code is enclosed
as a source file
Software,
algorithm
LaVision BioTec
ImSpector
microscopy
software
LaVision BioTec RRID:SCR_015249 https://www.lav
isionbiotec
.com/
Software,
algorithm
Fiji Fiji RRID:SCR_002285 http://fiji.sc
Software,
algorithm
Image J Image J - NIH RRID:SCR_003070 https://imagej
.nih.gov/ij/
Software,
algorithm
EthoVision XT 8.5 Noldus RRID:SCR_000441 https://www.
noldus.com
/EthoVision-XT/New
Software,
algorithm
Image lab Biorad RRID:SCR_014210 http://www.bio-rad.
com/en-us
/sku/1709690-image
-lab-software
Software,
algorithm
Oroboros
DatLab
Oroboros,
Innsbruck,
Austria
http://www.
oroboros.a
t/index.php?id
=datlab
Animals
All experimental procedures were performed in accordance with institutional animal welfare guide-
lines and were approved by the state government of Rhineland-Palatinate, Germany (G14-1-010 and
G14-1-017). WT littermates and heterozygous Hdh(CAG)150 mice (Hdh150, RRID:IMSR_JAX:004595)
carrying an extended CAG sequence (~150) replacing the normal length CAG sequence in mouse
Htt gene were obtained by crossing Hdh150 heterozygous with WT mice (Lin et al., 2001).
Male mice at 10 – 15 weeks of age were used to examine the change in neuronal network activity
prior to disease onset and at 14 – 17 weeks of age to examine the effect of in vivo metformin treat-
ment. Male mice at 12 – 16 weeks of age were used for behavior studies. Male mice at 13 weeks of
age were used for immunohistochemistry. The mice were kept under specific-pathogen-free condi-
tions on a 12 hr light/12 hr darkness cycle with free access to water and food. Mice were genotyped
using the primers 5’-CCC ATT CAT TGC CTT GCT GCT AGG-3’ and 5’-CCT CTG GAC AGG GAA
CAG TGT TGG-3’ (Sigma-Aldrich) producing 379- and 829-bp-long fragments for WT and mutant
alleles, respectively.
Surgery for in vivo two-photon Ca2+ imaging
Mice were prepared for in vivo imaging under isoflurane (1 – 1.5% in pure O2, AbbVie). Anesthesia
depth was assessed by monitoring pinch withdrawal and respiration rate. Body temperature was
kept at 37˚C with a heating pad (ATC 200, World precision instruments). Local anesthesia (2% xylo-
caine, AstraZeneca) was applied to the scalp. A custom-made recording chamber was glued to the
skull with cyanoacrylic glue (UHU) followed by dental cement (Paladur, Heraeus). Then, a craniotomy
of 1.5  1.5 mm was performed using stainless steel drill bits. The position of the primary visual cor-
tex was located according to brain atlas coordinates (Bregma  3 to  4.5 mm, 2 – 3 mm lateral to
the midline) (Paxinos and Franklin, 2001). After surgery, the mouse was subjected to the two-pho-
ton imaging setup.
Two-photon Ca2+ imaging
The fluorescent Oregon-Green BAPTA1 AM (OGB-1 AM, O6807, Molecular Probes) was bulked-
loaded in the visual cortex as described previously (Stosiek et al., 2003). Anesthesia level was con-
tinuously monitored by keeping the breathing rate at 100 – 110 breaths/min. High-speed two-
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photon Ca2+ imaging was performed in layer 2/3 (150 to 350 mm from the pial surface) with an
upright LaVision BioTec TrimScope II resonant scanning microscope, equipped with a Ti:sapphire
excitation laser (Chameleon Ultra II, Coherent) and a 25x (1.1 N.A., MRD77220, Nikon) or 40x (0.8
N.A., NIRAPO, Nikon) objective. The laser was tuned to 800 nm and fluorescence emission was iso-
lated using a band-pass filter (525/50, Semrock) and detected using a GaAsP photomultiplier tube
(PMT; H7422-40, Hamamatsu). The TriM Scope II scan head, equipped with a resonant scanner,
imaged time-lapses (512  512 pixels,~440  440 mm field of view) at a maximum frame rate of 30.4
Hz. Time lapses were recorded for 5 – 8 min on average. Imspector software (LaVision BioTec) was
used for microscope control and image acquisition.
Determining cell number and analysis of Ca2+ transients
First, the number of cells loaded with OGB-1 was manually counted in ImageJ (National Institutes of
Health). The area containing all the cells was traced freehand and calculated by the software. Func-
tional data were analyzed using custom-written functions in MATLAB R2011a (Mathworks, Natick,
MA) and Igor Pro 6.22 – 6.37 (Wavemetrics, Inc., Lake Oswego, OR). The code is attached as Fig-
ure 1—source data 2. Regions of interest (ROIs) were hand-drawn by tracing the outlines of OGB1-
positive neurons. Fluorescence intensities were quantified by averaging pixels inside each ROI for
every image in a sequence. The fluorescence values were normalized by user-defined baseline. Spe-
cifically, dF/F was defined as the following:
dF
F
¼
mean fluorescence inside an ROI
mean user  defined baseline
  1
 
 100
where the baseline is defined as a mean fluorescence from a 1–3 s silent period in the same ROI.
The peak of a Ca2+ transient was defined as the first derivative to crossed zero, and the second
derivative to be negative, and where the amplitude to be greater than three standard deviations
(SD) above the mean. The peak location was corrected manually where necessary. Each dF/F trace,
sampled at 15.2 – 30.4 Hz sampling frequency, was preprocessed by binomial Gaussian smoothing
(20 – 40 iterations) followed by a high pass filter. The baseline was estimated as the median of activ-
ity-free 10 s period preceding each peak. The foot and the tail of Ca2+ transients were determined
as the first data point that fell within 0.5 SD of the baseline before and after the peak, respectively.
The area under the curve was trapezoidal and measured between the foot and the tail. A distribution
histogram of neurons according to their Ca2+ transient frequency was used to segregate neurons
into three functional subgroups. The definition of hyperactive neurons (>3 trans/min) was deter-
mined by the absence of neurons above this limit in WT (0.4 ± 0.3%). The criterion used for low
active neurons was set to comprise ~25% of the WT neuronal population (25.8 ± 3.9%).
The distance between two neurons was calculated by Pythagorean theorem after the x,y coordi-
nate was determined for each ROI.
The randomization of experimental data comprised two steps: first, each raster plot was reas-
signed to a randomly selected ROI; then, the location of the individual raster event was shuffled ran-
domly, except no spikes were allowed to occur within 1 s of each other.
Immunohistochemistry
Mice were anesthetized with a mixture of ketamine/xylocaine and perfused transcardially with 4%
paraformaldehyde (#15710, Life technologies) in 0.1M phosphate buffer and brains were post-fixed.
50-mm-thick sections were sliced using a HM650 V vibratome (ThermoFisher) and collected in phos-
phate buffer saline (PBS; Life technologies). Floating sections were incubated for 1 hr with PBS con-
taining 4% natural goat serum (NGS, ab7481, Abcam) or 4% natural donkey serum (NDS, ab7475,
Abcam) and 1% Triton X-100 (Sigma-Aldrich) at room temperature (RT, 22˚C). Slices were then incu-
bated for 48 hr at 4˚C with primary antibodies against the apoptotic marker-cleaved caspase-3
(1:500; rabbit polyclonal; 9661, Cell signaling), neuronal marker NeuN (1:500; mouse monoclonal;
MAB377, Millipore) or astrocytic marker GFAP (1:1500; rabbit polyclonal; Z0334, Dako). Slices were
incubated for 2 hr at RT with secondary antibody Alexa 546 goat anti-rabbit (1:300, A11035, Invitro-
gen), Alexa 647 goat anti-mouse (1:300, A21235, Invitrogen) or Cy2 donkey anti-rabbit (711-225-
152, Jackson Immuno Research). Primary and secondary antibodies were diluted in PBS containing
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2% NGS or 2% NDS and 0.2% Triton X-100. After staining, brain slices were mounted with Fluorosh-
ield Mounting Medium (ab104135, Abcam).
For Htt staining, brains were embedded in tissue tek (Sakura) and frozen on dry ice with 100%
ethanol. 5 – 10 mm sagittal sections were sliced and subjected to antigen retrieval by being placed in
10 mM sodium citrate buffer at 84˚C or 90 – 95˚C for 15 – 20 min and rinsed with TBS-Triton-X
(0.3%, Roth). Subsequently, sections were blocked with 20% sheep or horse serum in TBS-Triton-X
for 1 hr at RT. Primary antibody (Htt: 1:200, rabbit monoclonal, ab109115, Abcam) was diluted in
TBS-Triton-X and incubated overnight at 4˚C. Secondary antibody (1:200, goat anti-rabbit AlexaFluor
488, A11008, Life technologies) in TBS-Triton-X was incubated for 2 hr at RT. Afterwards, sections
were embedded in fluoromount (Sigma-Aldrich) including Hoechst33342 (1:1000, B2261, Sigma-
Aldrich). Mounted slices were analyzed with a confocal laser-scanning microscope (Leica SP8).
Sample preparation for respirometry experiments
Experimental animals were sacrificed by cervical dislocation immediately before OXPHOS analysis.
Brains were micro-dissected on ice and specimens weighed on an analytical balance (Sartorius,
CPA1003S; Germany). The micro-dissected brain regions were directly transferred into ice-cold mito-
chondrial respiration medium MiR05 (EGTA 0.5 mM, MgCl23 mM, K-lactobionate 60 mM, taurine 20
mM, KH2PO410 mM, HEPES 20 mM, sucrose 110 mM, BSA 1 g/L, adjusted to pH 7.1)
(Kuznetsov et al., 2000). The tissue was then homogenized in a pre-cooled 1.5 ml tube with a
motorized pestle in MiR05 medium with 10 strokes. Resulting homogenates containing 10 mg tissue
wet weight were suspended in 100 ml of ice-cold MiR05 and later 20 ml (2 mg) from the 100 ml tissue
suspension was added to each chamber of the Oxygraph-2k, Oroboros Instrument containing 2 ml
of MiR05 for OXPHOS analysis (Holmstro¨m et al., 2012). All chemicals were purchased from Sigma-
Aldrich, Germany. The optimized motorized pestle preparation of brain tissue yields a high degree
of permeabilization as evident by the minimal effect of digitonin titrations on OXPHOS capacity.
Therefore, digitonin is not necessary for this protocol.
High-resolution respirometry in tissue
Tissue homogenates were transferred into calibrated Oxygraph-2k (O2k, Oroboros Instruments,
Innsbruck, Austria) 2 ml chambers. Oxygen polarography was performed at 37 ± 0.001˚C (electronic
Peltier regulation) in O2k chambers and oxygen concentration (mM) as well as oxygen flux per tissue
mass (pmol O2s
  1
mg  1) were recorded real-time using DatLab software (Oroboros Instruments
Innsbruck, Austria). A multisubstrate protocol was used to sequentially explore the various compo-
nents of mitochondrial respiratory capacity. The homogenate was suspended in MiR05, added to
the Oxygraph-2k glass chambers and the O2flux was allowed to stabilize. A substrate-uncoupler-
inhibitor titration (SUIT) protocol was applied to assess qualitative and quantitative mitochondrial
changes in Hdh150 transgenic mice and unaffected controls. After stabilization, LEAK respiration
was evaluated by adding the complex I (CI) substrates malate (2 mM), pyruvate (10 mM) and gluta-
mate (20 mM). The maximum oxidative phosphorylation (OXPHOS) capacity with CI substrates was
attained by the addition of ADP+Mg2+ (5 mM) (CIOXPHOS). For evaluation of maximum OXPHOS
capacity of the convergent input from CI and complex I I (CII) at saturating ADP-concentration, the
CII substrate succinate (10 mM) was added (CI +CIIOXPHOS). We then uncoupled respiration to exam-
ine the maximal capacity of the electron transport system (ETS or CI +IIETS) using the protonophore,
carbonylcyanide 4 (trifluoromethoxy) phenylhydrazone (FCCP; successive titrations of 0.2 mM until
maximal respiration rates were reached). We then examined consumption in the uncoupled state
solely due to the activity of complex I I by inhibiting complex I with the addition of rotenone (0.1
mM; ETS CII or CIIETS). Finally, electron transport through complex I II was inhibited by adding anti-
mycin A (2 mM) to obtain the level of residual oxygen consumption (ROX) due to oxidating side reac-
tions outside of mitochondrial respiration. The O2 flux obtained in each step of the protocol was
normalized by the wet weight of the tissue sample used for the analysis and in addition ROX was
subtracted from the fluxes in each run to correct for non-mitochondrial respiration (Hollis et al.,
2015). All respiration experiments comprise 2 – 3 counterbalanced blocks across days. All substrates
and inhibitors used were obtained from Sigma.
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Visual discrimination task
WT and presymptomatic VFDO Hdh150 mice (13 – 15 weeks of age) were isolated and food
deprived for 24 hr. Subsequently, they were placed into an operant chamber with a touchscreen
including two windows and a food dispenser on the opposite wall (Med Associates Inc; St. Albans).
In order to keep animals motivated to perform the task, their daily food intake was adjusted to main-
tain body weight at 75 – 80% of their initial body weight during the course of the experiment. The
experiment consisted of three phases:
1) mice were trained to collect a food pellet from the dispenser twice on day 1, 2) mice were
trained to nose poke the touchscreen to obtain food pellet reward. They needed to collect and con-
sume the pellet to proceed to the next trial. One daily session was either 30 min or 70 trials. The
touch training was over when mice reached 70 trials on three consecutive days. 3) For the visual dis-
crimination task, the screen presented two stimuli (pair 1: black vs. white or pair 2: black vs. grey),
one correct, one false, randomly presented left or right. The mice were trained to nose poke the cor-
rect stimulus, whereupon a pellet was released. Again, they needed to collect and consume the pel-
let to proceed to the next trial. One daily session was either 30 min or 100 trials. The task was
successful when the mice reached 70% correct trials on three consecutive days.
Open field test
Mice were not habituated to the set-up. Each mouse was removed from its home cage and put into
a holding box next to the testing box. Subsequently, the mouse was put into the testing box facing
the rear wall. The mice had time to explore the area for 5 min. Time in the center, which was deter-
mined as 10 cm away from each wall of the box, was measured automatically by EthoVision XT 8.5,
when the center-point of the mouse moved into it.
Cell lines and filter retardation assay
For all cell lines used in this study the identity has been authenticated and mycoplasma contamina-
tion has been tested and excluded.
HEKT cell lines (ATCC, RRID:CVCL_1926) stably expressing FLAG-tagged HTT-exon 1 with either
51 or 83 CAG repeats under the control of a Tet-off promotor as well as the filter retardation assay
were described previously (Scherzinger et al., 1997).
For the filter retardation assay cells were either transfected with a pool of MID1 specific siRNA
oligonucleotides (AATTGACAGAGGAGTGTGATC, CACCGCAUCCUAGUAUCACACTT, CAGGA
UUACAACUUUUAGGAATT, TTGAGTGAGCGCTATGACAAA, AAGGTGATGAGGCTTCGCAAA,
TAGAACGTGATGAGTCATCAT) or non-silencing control oligonucleotides (AATTCTCCGAACGTG
TCACGT) using Oligofectamine (Thermo Fisher Scientific) or treated with metformin at a final con-
centration of 1 mM and 2.5 mM for 24 hr. Cell lysates were soaked through a filter membrane and
aggregates were detected using monoclonal anti-FLAG M2-Peroxidase (HRP) antibodies (Sigma-
Aldrich). Signals were quantified using the Fiji Software.
FRAP (fluorescence recovery after photobleaching)-based assay
Neuro-2A (a mouse neuroblastoma cell line, ATCC, RRID:CVCL_0470) cells or murine primary corti-
cal neurons (prepared from NMRI mice E14.5 as described previously [Kickstein et al., 2010] were
transfected with constructs expressing Htt exon1 with 49CAG repeats fused to GFP (vector pEGFP-
C1-HTTex1; an N-terminal GFP tag) the day before analysis. Cells were analyzed in a previously
established FRAP-based assay to monitor translation in living cells (Krauss et al., 2013) using a Zeiss
LSM700 confocal microscope. In brief, in contrast to standard FRAP, the GFP-signal of the entire cell
was bleached using a 488 nm argon laser and fluorescence recovery was imaged over a time frame
of 4 hr. The fluorescence signal was quantified as the sum of the pixel over the cell area, and the
resulting total cell fluorescence was normalized to the post-bleach signal, which was set to 100%.
Fluorescence recovery curves represent mean ± SEM of at least 35 cells.
Caenorhabditis elegans
The following C. elegans strains was used: strain AM141, genotype rmIs133 [unc-54p::Q40::YFP]
(RRID:WB-STRAIN:AM141). AM141 worms express YFP that is linked to a polyglutamine stretch of
40 glutamines (Q40) in the muscle cells of the body wall. In the early lifetime of the worms YFP-Q40
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is soluble and it aggregates gradually over time. This strain is used as a model for polyglutamine dis-
eases like Huntington´s disease, since the 40Q represents a pathological range of the polyglutamine
stretch.
For the treatment with metformin, NGM plates were seeded with OP50 bacteria and dried over-
night. For heat inactivation OP50 bacteria were incubated at 70˚C for 30 min. Metformin in a con-
centration of 5 mM, 10 mM or 500 mM was added the next day and dried again before usage.
Worms were then put onto the plates and aggregates and liquid trashing were quantified after 5
days.
Nematodes were synchronized by hypochloride treatment. At day 5 of adulthood the worms
were analyzed. Aggregates were counted under a fluorescence stereo microscope after anesthetiz-
ing the worms with 25 mM Levamisol on a coverslip. For each experiment 15 – 20 animals were
counted. In addition, liquid thrashing was analyzed in 10 – 15 animals per experiment. Therefore, sin-
gle worms were transferred into one drop of M9 buffer (3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 ml 1
M MgSO4, H2O to 1 liter) and the rhythmic bending of the worm around its body axis was counted
for 30 s. Each experiment was conducted at least three times.
Western blots
For western blotting mice were sacrificed and brains were grinded and shaked in magic mix (48%
urea, 15 mM TRIS-HCl (pH7.5), 8.7% glycerin, 1% SDS, 1% mercaptoethanol, complete protease
inhibitors (Roche), Phosstop (Roche)) at 4˚C with add-on homogenization (QIAshredder). Afterwards,
samples were boiled at 95˚C and 30 mg protein lysate (40 mg for Htt blot) was loaded on a 10% SDS
PAGE gel, resolved (overnight at 100 V for separation of mHtt from wtHtt) and blotted onto a PVDF
membrane (BioRad) using TransBlot Turbo (BioRad). Membranes were then blocked with 1% BSA
(pS6) or 5% milk (Actin, Gapdh, Htt) in PBS-Tween20 (Roth) and incubated with primary antibody
(Actin: 1:2000, A2066, Sigma Aldrich; pS6: 1:2000, 2215, cell signaling; Gapdh: 1:2000, ab8245,
abcam; Htt: 1:850, ab109115, abcam) in blocking buffer overnight. Membranes were then washed
three times with PBS-Tween20 and subsequently incubated with secondary antibody (1:6000, for Htt
1:4000, Donkey anti-rabbit or anti-mouse, Jackson Immuno Research) for 1 hr in blocking buffer.
Subsequently, membranes were again washed three times with PBS-Tween20. Chemiluminescent
detection was done by using Western Lightning Plus-ECL (PerkinElmer). Visualisation was performed
on a ChemiDoc MP Imaging System (Biorad). Quantification of resulting bands was performed using
Image Lab (version 5.2.1).
Metformin treatment in vivo
Both the Hdh150 and WT mice received chronic metformin (MP Biomedicals, LLC; France) adminis-
tration (5 mg/ml in the drinking water) freshly prepared every day for 3 weeks starting from an age
of 9 – 10 weeks.
Statistics
Statistical significance was tested in GraphPad Prism (GraphPad Software Inc., La Jolla, CA). Table 1
contains all details concerning statistical tests used (name of the test, p-values, F values and degree
of freedom). *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. For all data, we first tested for nor-
mal distribution using the one-sample Kolmogorov-Smirnov test. In case that the null hypothesis of a
normal distribution could not be rejected (for p>0.05), we employed a parametric test, if H0 could
be rejected (for p<0.05) we used non-parametric tests: Mann-Whitney U test for non-parametric
data and t test for parametric data. Pearson’s correlation coefficient was used on raster plots that
were temporally binned (328 ms per bin) to compare activity patterns between pairs of neurons.
Box-and-whisker plots indicate the median (line) of average values from multiple time-lapses, the 25-
75th percentiles (box) and the 10-90th percentiles (whiskers). Graphs show mean ±s.e.m (standard
error of the mean).
Data availability
Values used in figures are available on Dryad Digital repository (doi:10.5061/dryad.g3b5272) and
the code used for the analysis of calcium imaging is in Figure 1—source data 2.
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